Abstract
The CMC regulatory compliance impact of the manufacture of the biopharmaceutical drug product due to the choice of formulation composition, coupled with the choice of the product-compatible container closure system, is examined. Also, the various manufacturing processes to conjugate a protein to a chemical (e.g., PEGylation) or to a drug (e.g., ADC) prior to formulation is discussed. The criticality of carrying out the filling and sealing process of the drug product under GMP aseptic conditions to obtain sterile injectable biopharmaceutical drug products is presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.